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Background aims. Transplantation is the gold standard procedure for treating acute and chronic end-stage liver diseases.
Given the shortage of organs, the development of cellular sources other than human liver is urgent. The main objective of this
project was to examine the effect of mesenchymal stromal cell (MSC) (bone marrow, umbilical cord and liver MSCs)
intravenous injection on liver regeneration in a model of hepatic damage in NOD/SCID/IL non-obese diabetic/severe
combined immunodeﬁcient/Interleukin-2Rg(null) (NSG) mice. Methods. Mice received 3 intraperitoneal injections of CCl4
Carbon tetrachloride per week for 4 weeks. Forty-eight hours after the last injection of CCl4, mice received 500,000 MSCs or
phosphate-buffered saline by intravenous injection. We examined hepatic damage by means of quantitative image analysis
and blood enzyme analysis 24 h, 1 week or 8 weeks after MSC or phosphate-buffered saline injection. We also examined
MSC homing by means of real-time polymerase chain reaction of human albumin. Results. We adapted a model of liver
injury in immunodeﬁcient mice. In this model, accumulation of collagen in newly formed scar septa was apparent up to 8
weeks after CCl4 treatment. Human albumin DNA was found in all organs tested. However, intravenous MSC injection,
even after CXCR4 C-X-C chemokine receptor type 4 transduction and whatever the origin of MSCs, failed to improve liver
damage. Conclusions. In this liver injury model, MSCs were propagated in various tissues, particularly ﬁltering organs. For
the treatment of hepatic damage, intravenous administration of moderate doses of MSCs does not appear to be effective. Yet,
this adapted liver injury model is appropriate for investigating engraftment of human cells.
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Transplantation is the gold standard procedure for
treating acute and chronic end-stage liver diseases.
Given the shortage of organs, the development of
cellular sources other than human liver is urgent.
Mesenchymal stromal cells (MSCs) are multipotent
progenitors capable of differentiating into various
cells and tissues, such as chondrocytes, osteoblasts
and adipocytes [1]. MSCs have a promising thera-
peutic potential. In addition to their immunosup-
pressive [2] and pro-hematopoietic [3] properties,
these cells can give rise to other, even non-
mesodermal, cell types such as cardiomyocytes, he-
patocytes or neurons. This regenerative potential of
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within the broader population of MSCs. Indeed, af-
ter systemic administration, undifferentiated MSCs
have been shown to accelerate the resolution of an
acute liver injury [4]. Factors secreted by MSCs have
also been shown to promote hepatocyte proliferation
and regenerative responses in the early phase after
surgical resection [5].
It has been well established that systemically
infusedMSCs home to injured, inﬂamed or cancerous
tissues [6e8] and that intravenous MSC injection
results in the accumulation of MSCs within ﬁltering
organs such as the lungs, liver or spleen [9,10].
The main objective of this study was to examine
the effect of MSC intravenous (IV) injection on
liver regeneration in a model of hepatic damage inège, CHU Sart Tilman B35 1, Avenue de l’Hôpital, B-4000 Liège, Belgium.
ublished by Elsevier Inc. All rights reserved.
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immunodeﬁcient/Interleukin-2Rg(null) (NSG) mice.
We tested 3 MSC preparations: MSCs from bone
marrow, from umbilical cord and from liver.Methods
Cell isolation and preparation
All material was acquired with written informed
consent and used according to the guidelines estab-
lished by the Ethical Committee of the University
Hospital of Liège.Bone marrow MSCs
Human bone marrow MSCs were prepared as pre-
viously described [11]. However, in this study,
MSCs were cultured with 5% platelet lysate instead
of 10% fetal bovine serum.Liver MSCs
Mesenchymal-like cells from adult human liver (L)
were kindly provided by the laboratory of Pediatric
Hepatology and Cell Therapy of the Universite
Catholique de Louvain, Brussels, Belgium. These cells
were enzymatically isolated as described above [12].
Cells were seeded at a density of 5  103 cells/cm2
in Dulbecco’s Modiﬁed Eagle’s Medium þ 10% fetal
bovine serum and cultured on 5 mg/cm2 of type 1
collagen. When cultures reached 90% conﬂuence,
cells were detached with the use of the trypsine
ethylenediaminetetra-acetic acid solution.Umbilical cord MSCs
Human umbilical cord MSCs were prepared as
previously described [13]. MSCs were cultured in
Dulbecco’s Modiﬁed Eagle’s Medium þ 5% platelet
lysate.Flow cytometric analysis of MSC preparations
Phenotypic characterization of MSC was performed
as previously described [14].MSC differentiation assays
Fat, bone and cartilage differentiation assays were
carried out as described by Pittenger et al. [1] and
revealed by staining with oil red O, alizarin red and
toluidine blue, respectively [1]. Hepatogenic differ-
entiation assays were performed as described by
Najimi et al. [12] and revealed by periodic acideSchiff
staining.Liver injury model
NOD/SCID/IL-2Rg(null) (NSG) male mice
received 3 CCl4 3% intraperitoneal (IP) injections
per week during 4 weeks. Forty-eight hours after the
last injection, mice received 500,000 MSCs by
means of IV tail injection. We injected bone marrow
MSCs (BM-MSCs), liver MSCs (L-MSCs) or um-
bilical cord MSCs (UC-MSCs). We examined MSC
homing by means of real-time polymerase chain re-
action (PCR) and MSC function by means of
quantitative image analysis of sirius red staining and
blood enzyme assays.Homing of MSCs
Twenty-four hours (D1), 1 week (D7) or 8 weeks
(D56) after MSC injection, mice were killed by
cervical dislocation, and blood, bone marrow,
spleen, lungs, liver, kidneys and intestine were har-
vested and frozen. Genomic DNA was isolated from
murine tissues with the use of a DNeasy Blood &
Tissue Kit (Qiagen, KJ Venlo, The Netherlands).
DNA analyses were performed by use of real-time
PCR. Ampliﬁcation was performed with the use of
the LightCycler 480 Real-Time PCR System
(Roche, Mannheim, Germany). Relative quantities
of the human albumin gene were calculated through
the use of the relative standard curve method rec-
ommended by Applied Biosystems (Gent, Belgium).Quantitative image analysis of sirius red staining
As described previously [15], ﬁbrosis was evaluated
in mice by means of quantitative image analysis of
sections stained with sirius red to visualize collagen
ﬁbers. Images were acquired with a Zeiss Axiovert
25 microscope (Carl Zeiss Microscopy, Jena, Ger-
many) equipped with the use of an AxioCam cam-
era, and quantitative data were obtained with the use
of the KS 400 imaging system. The analysis was
performed on 6 ﬁelds per section with a 20
magniﬁcation. Stained vessel walls were systemati-
cally excluded to quantify only the ﬁbrotic scar septa.
Fibrosis was expressed as the mean percentage of the
sirius redestained areas out of the total ﬁeld tissue
area.Blood enzyme assays
As a quantitative measure of liver injury by CCl4, the
activity of alanine aminotransferase (ALAT) and
aspartate aminotransferase (ASAT) and the quantity
of albumin in the plasma were determined with the
use of commercially available kits (Roche) according
to the manufacturer’s instructions.
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To induce the expression of CXCR4, we transduced
MSCs through the use of lentiviral vectors. For
this purpose, complementaryDNA constructs PBMN-
IRES-eGFP-hCXCR4wt (gift from Dr A. Richmond,
Nashville, TN, USA) and pLenti6MCS (Life Tech-
nologies Europe B.V., Gent, Belgium) were digested
with the restriction enzymes EcoRI/XhoI and puriﬁed
by means of electroelution and column, respectively.
The CXCR4 complementary DNA was then ligated
into the pLenti6MCS constructs. Lentiviral vectors
were produced by transient transfection of Lenti-X
293T cell lines (Clontech 632180, Leusden, The
Netherlands). We conﬁrmed CXCR4 expression in
MSCs by ﬂuorescence-activated cell sorting (FACS)
with phycoerythrin-conjugated anti-CXCR4antibodies
(BD Biosciences, Erembodegem, Belgium). Data were
acquired on a BD FACSCanto II ﬂow cytometer and
analyzed by use of BD FACSDiVa software.Statistical analysis
Results are reported as medians. Comparisons were
made with the use of the Mann-Whitney test. Sta-
tistical analyses were performed with the use of
GraphPad Prism 5.00 Software (La Jolla, CA, USA).Results
MSCs from BM, UC and liver have a mesenchymal
phenotype and quadri-lineage differentiation capacity
In this study, we tested 3 MSC preparations: BM-
MSCs, UC-MSCs and L-MSCs. Their phenotype
and differentiation potential were assessed. MSCs of
the 3 origins displayed a characteristic mesenchymal
phenotype, being negative for CD14, CD36 and
CD45, weakly positive for CD49a and positive for
CD13, CD73, CD90, CD105 and CD146 antigens.
Cells did not express antigens previously reported on
MSCs such as CD271 and SSEA4 antigens [16,17]
(data not shown). There were differences in pheno-
type: BM-MSCs expressed statistically more CD13,
CD90 and CD146 antigens than did UC-MSCs and
L-MSCs (data not shown). The ability to differentiate
into hepatocytes, fat, bone and cartilage was present in
allMSCpreparations of the 3 origins (data not shown).CCl4 IP injections induce liver ﬁbrosis in NSG mice
To determine whether the model of Kesteloot [15] is
effective to induce liver ﬁbrosis in NOD/SCID/IL-
2Rg(null) (NSG) mice, animals received 3 CCl4 3%
IP injections per week during 4 weeks. Forty-eight
hours after the last injection, mice receivedphosphate-buffered saline (PBS) by IV tail injection.
We examined hepatic damage by use of quantitative
image analysis of sirius red staining and blood
enzyme analysis 24 h (D1), 1 week (D7) or 8 weeks
(D56) after PBS injection (Figure 1A).
Digital image analysis was used to quantify the
stained hepatic collagen accumulating speciﬁcally in
newly formed scar septa after the systematic exclusion
of the stained vessel walls. Collagen percentage was
signiﬁcantly increased after liver injury by CCl4.
Compared with normal mice, this percentage was 8.8-
fold (P < 0.001), 6.2-fold (P < 0.001) and 7.7-fold
(P < 0.01) higher on D1, D7 and D56, respectively
(Figure 1B). Compared with normal mice (35.5 g/L;
range, 34e37), plasma albumin was signiﬁcantly
decreased onD7 (34 g/L; range, 31e36,P< 0.05) and
D56 (33 g/L; range, 32e35, P < 0.05) but not yet on
D1 (35g/L; range, 34e39) (Figure 1C).PlasmaALAT
and ASATwere 2.6-fold (P< 0.01) and 1.7-fold (P<
0.05) higher, respectively, than in normal mice, but
decreased atD7 andD56 (Figure 1D,E).Thedecrease
of plasma albumin and the increase of plasma ALAT
and ASAT are the hallmarks of liver injury.MSC homing to the liver and other organs after IV
injection in a liver injury model
To determine whether MSCs home to the liver after
IV injection in mice with hepatic damage, we tested
by real-time PCR the presence of human albumin
DNA in blood, bone marrow, spleen, lungs, liver,
kidneys and intestine of mice 24 h (D1), 1 week (D7)
or 8 weeks (D56) after MSC injection (Online
Supplementary Figure S1A).
HumanalbuminDNAwas found inall testedorgans,
particularly the liver, kidneys and lungs. OnD1, human
DNA quantity was always higher in the lungs compared
with other organs and was always smaller in the bone
marrow, independent of the origin of MSC (Online
Supplementary Table S2). In the lungs, the percentage
ofmice positive for human albumin decreased over time,
suggesting MSC trapping in the lungs before reaching
other organs (Online SupplementaryTable S1).Human
DNA quantity as well as percentages of mice positive
for human albumin were more stable over time in the
kidneys, spleen, intestine and bone marrow (Online
Supplementary Table S1eS2).
In the liver, onD1, 2-fold and1.6-foldmorehuman
DNA was detected after BM-MSC and UC-MSC in-
jection compared with L-MSC injection (P < 0.005).
On D56, the proportion of mice positive for human
albumin in the liver in the UC-MSC group (30%) was
lower than in the BM-MSC (71%) or L-MSC (54%)
groups (Online Supplementary Table S1), but, when
positive, the amount of human DNA was higher after
UC-MSC injection compared with BM-MSC
Figure 1. Establishment of a model of hepatic damage in NSG mice: mice received 3 IP injections of 3% CCl4 per week for 4 weeks. Forty-
eight hours after the last injection of CCl4, mice received PBS by IV tail injection. Hepatic damage was evaluated by means of quantitative
image analysis of sirius red staining and blood enzyme measurement at D1, D7 and D56. (A) Design of the study. (B) Relative ﬁbrosis area.
(C) Plasma albumin. (D) Plasma ALAT. (E) Plasma ASAT. Each symbol represents 1 mouse. Line represents median values (n  8, Mann-
Whitney test).
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DNA quantity was stable over time after injection of L-
MSCs or UC-MSCs (Online Supplementary
Figure S1B). After injection of BM-MSCs, human
DNA quantity decreased 2.2-fold and 1.6-fold onD56
compared with D1 (P < 0.001) and D7 (P < 0.05),
respectively (Online Supplementary Figure S1B).IV injection of MSCs fails to improve liver damage
NSG mice received 3 IP injections of CCl4 per week
for 4 weeks. Forty-eight hours after the last injection,
groups of mice received 500,000 MSCs of the 3 or-
igins by IV tail injection. We examined hepaticdamage by means of quantitative image analysis of
sirius red staining and blood enzyme measurement
24 h (D1), 1 week (D7) or 8 weeks (D56) after PBS
or MSC injection (Figure 2A).
Relative ﬁbrosis areas on D1, D7 and D56 were
comparable in the PBS and MSC groups. Thus,
treatment with MSCs of the 3 origins did not show an
effect on the ﬁbrosis (Figure 2B). Similarly,MSCs had
no effect on plasma albumin, except for a weak dif-
ference onD7 between L-MSCs and PBS and onD56
between BM-MSCs and PBS (Figure 2C). Finally,
plasmaASATandALAT levelswerenot inﬂuencedby
MSC injection (Figure 2D). In this model, IV MSC
injection thus failed to improve liver damage.
Figure 2. Analysis of the effect of IV injection of MSCs in NSG mice with hepatic damage. (A) Design: mice received 3 IP injections of 3%
CCl4 per week for 4 weeks. Forty-eight hours after the last injection of CCl4, mice received 500,000 MSCs or PBS by IV tail injection. Liver
damage was evaluated by means of quantitative image analysis of sirius red staining and blood enzyme measurement at D1, D7 and D56.
Mice received BM-MSCs, UC-MSCs or L-MSCs. (B) Relative ﬁbrosis area. (C) Plasma albumin. (D) Plasma ALAT. (E) Plasma ASAT.
Each symbol represents 1 mouse. Line represents the median (n  8, Mann-Whitney test). Dotted lines represent the minimum and
maximum and the solid line the median values of normal mice.
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1516 A. Briquet et al.CXCR4 transduction of MSCs does not promote liver
homing or liver repair
PCR results showed that only a fraction of injected
MSCs reached the liver. To promote homing of
MSCs to the liver and hence liver repair, MSCs from
BM, UC or liver were transduced with lentiviral par-
ticles to induce the expression of CXCR4. After
transduction, we showed by means of FACS that
>50% of MSCs highly expressed CXCR4 (data not
shown). These cells were injected IV into mice with
liver injury. We studied the biodistribution of MSCs
by real-time PCR and analyzed hepatic markers.
CXCR4þMSCs homing to the liver was not increased
compared with standard MSCs (data not shown). We
could not show a beneﬁcial effect of CXCR4þMSC
injection whatever the source of MSCs (Figure 3).Discussion
In this study, we adapted a liver injury model in
immunodeﬁcient mice. As described before [18],
CCl4 IP injections induced liver ﬁbrosis; we observed
an accumulation of collagen in newly formed scar
septa. Liver ﬁbrosis was maintained up to 8 weeksFigure 3. Analysis of the effect of IV injection of CXCR4þMSCs in NS
CCl4 per week for 4 weeks. Forty-eight hours after the last injection of CC
damage was evaluated by means of quantitative image analysis of sirius r
Mice received BM-MSCs, UC-MSCs or L-MSCs. (A) Relative ﬁbrosis
Each symbol represents 1 mouse. Line represents the median (n  3
maximum and the solid line the median values of normal mice.after stopping CCl4 treatment. Plasma albumin was
signiﬁcantly decreased on D7 and D56 but not yet
on D1. The delayed decrease in plasma albumin
compared with the appearance of liver ﬁbrosis is
certainly a result of the long half-life of albumin
(3 weeks). Plasma alanine and aspartate amino-
transferases were increased to levels described pre-
viously [5,19,20]. Decreased plasma albumin and
increased plasma alanine and aspartate aminotrans-
ferases are the hallmarks of liver injury.
Although BM-MSCs, UC-MSCs and L-MSCs
met the criteria of the International Society for
Cellular Therapy [21], BM-MSCs expressed more
CD13, CD90 and CD146 antigens than did UC-
MSCs and L-MSCs, conﬁrming that these three
populations are not exactly the same. Moreover, they
do not migrate in the same fashion after IV injection.
Indeed, we observed more human DNA in the
spleen when mice received UC-MSCs. We also
observed more human DNA in the intestine or bone
marrow when mice received BM-MSCs (see Online
Supplementary Material). This suggests that tissue
origin would affect homing of MSCs. Some have
shown that depending on the tissue of origin, MSCs
did not express the same growth factors [22]; othersG mice with hepatic damage. Mice received 3 IP injections of 3%
l4, mice received 500,000 MSCs or PBS by IV tail injection. Liver
ed staining and blood enzyme measurements at D1, D7 and D56.
area. (B) Plasma albumin. (C) Plasma ALAT. (D) Plasma ASAT.
, Mann-Whitney test). Dotted lines represent the minimum and
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affect their immunoregulatory properties [23,24].
This conﬁrms that the choice of MSC tissue source
may be paramount to their use in cellular therapy.
In our model, we could not show a beneﬁcial ef-
fect of MSC injection whatever the origin of these
cells. No effect on ﬁbrosis, plasma albumin or plasma
alanine/aspartate aminotransferases was observed.
Two explanations are possible. First, the number of
MSCs used may not be sufﬁcient. In this work, we
injected only 500,000 MSCs per mouse, a dose
calculated to correspond to 20  106 MSCs/kg.
However, other studies used 1 million [18,25] or
even several million [26,27] MSCs per injection.
These studies have shown beneﬁcial effects of cell
injection (ie, reduction of plasma aminotransferase
levels or stimulation of endogenous liver regenera-
tion). We tried to inject >500,000 MSCs but the
mice died a few minutes later of pulmonary embo-
lism. The second explanation possibly relates to the
injection route. In this study, we showed that MSCs
of the 3 origins could migrate to the liver and stay
there up to 8 weeks after IV injection. However,
MSCs also migrated to other organs such as the
lungs, kidneys, spleen or intestine. Hence, after IV
injection, only a fraction of injected MSCs reaches
the liver. More direct injection into the portal circu-
lation or the promotion of cell homing to the liver
may provide more efﬁcient homing. To increase
MSC homing to the liver and thereby liver repair,
MSCs were transduced with lentiviral particles to
induce the expression of CXCR4. CXCR4 is a che-
mokine receptor binding to SDF-1, a molecule
expressed in various organs including the injured
liver [28]. Despite high expression of CXCR4 on
transduced cells, we could not show a beneﬁcial ef-
fect of CXCR4þMSC injection whatever the source
of these cells. Indeed, CXCR4þMSC homing to the
liver was not increased compared with control MSCs.
In conclusion, in this liver injury model, MSCs are
propagated in various tissues, particularly ﬁltering or-
gans such as the lungs, liver, spleen and kidneys. For the
treatment of hepatic damage, IV administration of
moderatedosesofMSCsdoesnot appear tobeeffective.Acknowledgments
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